| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SMARCB1 |
| Uniprot No | Q12824 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 141-376aa |
| 氨基酸序列 | HLDAVPCSTTINRNRMGRDKKRTFPLCFDDHDPAVIHENASQPEVLVPIRLDMEIDGQKLRDAFTWNMNEKLMTPEMFSEILCDDLDLNPLTFVPAIASAIRQQIESYPTDSILEDQSDQRVIIKLNIHVGNISLVDQFEWDMSEKENSPEKFALKLCSELGLGGEFVTTIAYSIRGQLSWHQKTYAFSENPLPTVEIAIRNTGDADQWCPLLETLTDAEMEKKIRDQDRNTRRMR |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SMARCB1重组蛋白的3篇参考文献，涵盖功能、结构及疾病机制研究：
---
1. **文献名称**：*Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy*
**作者**：Kadoch, C. et al.
**摘要**：研究利用重组SMARCB1蛋白解析SWI/SNF复合体的组装机制，发现其缺失导致染色质重塑异常，并与多种癌症(如横纹肌样瘤)的发生相关。
2. **文献名称**：*Structure of the SWI/SNF nucleosome remodeler bound to a nucleosome*
**作者**：Mashtalir, N. et al.
**摘要**：通过重组SMARCB1蛋白的冷冻电镜结构分析，揭示其在核小体重塑中的关键作用，阐明复合体与DNA结合的分子基础。
3. **文献名称**：*SMARCB1 loss activates autophagy in malignant rhabdoid tumors via reduced mTORC1 activity*
**作者**：Wang, X. et al.
**摘要**：利用重组SMARCB1蛋白进行功能恢复实验，证明其缺失通过mTOR通路激活自噬，为靶向治疗提供理论依据。
---
这些研究通过重组蛋白技术，深入探讨了SMARCB1的结构、功能及病理机制，为相关疾病治疗提供了重要线索。
SMARCB1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1), also known as INI1 or BAF47. is a critical component of the SWI/SNF chromatin remodeling complex. This multi-subunit complex regulates gene expression by altering nucleosome positioning, enabling access to DNA for transcription factors. SMARCB1 functions as a tumor suppressor, with its loss or mutation linked to aggressive cancers such as malignant rhabdoid tumors, epithelioid sarcoma, and certain schwannomas. Its role in maintaining chromatin structure and epigenetic regulation makes it essential for cellular differentiation, proliferation, and genome stability.
Recombinant SMARCB1 protein is engineered for research and therapeutic applications, typically produced via bacterial (e.g., E. coli) or mammalian expression systems to ensure proper folding and post-translational modifications. Purification methods often involve affinity chromatography tags (e.g., His-tag) followed by rigorous quality control to confirm activity and purity. This recombinant form enables structural studies (e.g., X-ray crystallography, cryo-EM) to elucidate its interactions within the SWI/SNF complex and with chromatin. It also serves as a tool for functional assays, such as chromatin remodeling activity measurements or screening for compounds that restore SWI/SNF function in SMARCB1-deficient cancers. Additionally, recombinant SMARCB1 supports gene therapy research aimed at reintroducing functional protein into tumors harboring SMARCB1 deletions. Challenges include preserving its stability in vitro and mimicking native complex assembly. Ongoing studies focus on leveraging recombinant SMARCB1 to decode its tumor-suppressive mechanisms and develop targeted therapies for SMARCB1-associated malignancies.
×
